Particularly interesting considering the drug is repurposed (IXC's Presendin, is AstraZeneca's Exenatide, of course different indications)
I havent read anything regarding tolerance for that indication, I guess we will find out in the longer term phase 3 if for the indication of IIH a tolerance-like effect is experienced in longer term use of Presendin for those concerned symptoms/endpoints.
Super interesting mate, thank you. If time permits, I and Im sure many others would love further insights surrounding what IXC are doing here.
Ann: Phase II Clinical Results and Capital Raising Presentation, page-15
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.335M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28320 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 22452 | 2 |
View Market Depth
| Last trade - 16.12pm 06/09/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable